Rocuronium Inhibitors
1 drugsAbout Rocuronium
Rocuronium is a neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor, preventing nerve impulses and causing muscle relaxation. It is used in anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.
Rocuronium's clinical importance lies in its rapid onset and intermediate duration of action, making it valuable in anesthesia and critical care. There is currently no genetic evidence data available for rocuronium.
BRIDION (sugammadex) is the only FDA-approved drug used to reverse the effects of rocuronium. It is a small molecule drug marketed by Merck, with approvals beginning in 2015.
Top Rocuronium Drugs
Merck is the only company with an approved drug related to rocuronium.
Low competition suggests high barriers to entry or limited market potential for new entrants.
Rocuronium Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Rocuronium, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel reversal strategies.
Rocuronium Clinical Trials 106 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Rocuronium. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 3 | 3 | 0 | 50% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
| Phase 3 | 20 | 19 | 0 | 1 | 100% |
| Phase 4 | 76 | 64 | 9 | 3 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Rocuronium Drug Approval Timeline (2015 - 2015)
The first and only drug approval for rocuronium was in 2015.
The stagnant approval timeline indicates a mature market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 73 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Rocuronium. A trial counts if an approved drug acting on Rocuronium is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.